Gilead Sciences announced the appointment of Dietmar Berger, formerly Sanofi’s chief medical officer, to the same role at Gilead. Berger will succeed Merdad Parsey, who is departing in early 2024. Berger’s tenure begins on January 2nd.
At Sanofi, Berger held the position of chief medical officer and global head of development. His responsibilities encompassed development science, strategy, and operations across Sanofi’s therapeutic areas. This experience aligns with Gilead’s increasing focus on oncology and inflammatory disease treatments.
Daniel O’Day, CEO of Gilead, emphasized Berger’s “exceptional leadership in global drug development,” highlighting his successful history of delivering transformative therapies and extensive experience. O’Day believes these qualities make Berger the perfect fit for Gilead’s Chief Medical Officer position.
In his new role, Berger will oversee Gilead’s virology, oncology, and inflammation portfolios. He will also lead the company’s global development and medical affairs organizations. Berger’s previous experience includes senior development roles at Bayer and Amgen.
This strategic appointment signals Gilead’s commitment to advancing its pipeline in key therapeutic areas. Berger’s leadership is expected to play a crucial role in driving innovation and growth for the company.
